One can sell Ranbaxy Laboratories on rally, says Sudarshan Sukhani of s2analytics.com.

Sell Ranbaxy Laboratories on upside, says Sudarshan Sukhani

One may sell on a little more upside in Ranbaxy Laboratories as the market was choppy throughout the day, says Sudarshan Sukhani of s2analytics.com.

Go short on REC, PFC: Sudarshan Sukhani

Sudarshan Sukhani of s2analytics.com advises selling Rural Electrification Corporation and Power Finance Corporation as both are showing signs of weakness.

Short Ranbaxy Laboratories: Sudarshan Sukhani

Sudarshan Sukhani of s2analytics.com recommends selling Ranbaxy Laboratories but with every decline short selling becomes a risk.

Hold Ranbaxy Loboratories: Madan

Ashu Madan, President, Core Client Group of Religare Securities Ltd recommends holding Ranbaxy Laboratories.

Avoid Ranbaxy Laboratories: Sudarshan Sukhani

One can avoid Ranbaxy Laboratories as it is showing no signs of stability, says Sudarshan Sukhani of s2analytics.com.

Sell Ranbaxy Laboratories, says Sudarshan Sukhani

One can sell Ranbaxy Laboratories as it is breaking all support levels, says Sudarshan Sukhani of s2analytics.com.

Prefer Glenmark, Aurobindo, Cipla over Ranbaxy: SP Tulsian

SP Tulsian of sptulsian.com advises to prefer Glenmark Pharma, Aurobindo Pharma or Cipla over Ranbaxy Labs.

Citi view: How pharma sector is looking post Q4 debacle

Prashant Nair of Citi India told CNBC-TV18 that the pharma sector's valuations in current market downturn situation has held up well. He presents his views on buzzing stocks from the sector.

Stay away from Ranbaxy: SP Tulsian

SP Tulsian of sptulsian.com feels it is better if one takes a trading position in spite of having positive view on the pharma, one should remain away from the stock.

Ranbaxy Laboratories can pullback towards Rs 405: Kulkarni

Shardul Kulkarni of Angel Broking is of the view that, one can see a pullback in Ranbaxy Laboratories towards Rs 405-410 over the next couple of trading sessions.

Don't buy Ranbaxy, says Mehraboon Irani

Mehraboon Irani of Nirmal Bang Securities remains negative on Ranbaxy. He says one should not buy the stock. "I don't see any reasons why Ranbaxy should be going up in a hurry at least from the present levels," he adds.

Avoid JP Associates, Ranbaxy: Sukhani

Sudarshan Sukhani of s2analytics.com advises to avoid JP Associate and Ranbaxy at current levels. One can sell JP Associate on rally.

Go long in Ranbaxy Labs, Aurobindo Pharma: SP Tulsian

SP Tulsian of sptulsian.com advises to go long in Ranbaxy Labs and Aurobindo Pharma with a target of Rs 409 and Rs 180 respectively.

Don't buy Ranbaxy Laboratories: Sukhani

One should not buy Ranbaxy Laboratories, says Sudarshan Sukhani of s2analytics.com. "There is no support in the stock."

Like L&T over SBI; cautious on Ranbaxy, Wockhardt: PN Vijay

Portfolio Manager, PN Vijay is bullish on L&T despite the stock falling heavily on Thursday. He is bullish on the real estate sector. Also, he suggests buying pharma stock Wockhardt, on dips.

Exit Ranbaxy Labs around Rs 440-450, says Sanjeev Agarwal

According to Dynamix Research & Capital Management‘s CEO Sanjeev Agarwal, Ranbaxy may see a pullback around Rs 440-450. He said that would be a level to exit the stock.

Sell Ranbaxy Labs, advises Rajesh Agarwal

Eastern Financiers‘ Head of Research Rajesh Agarwal recommended selling Ranbaxy Labs. He said he wouldn‘t be surprised if this stock falls below Rs 350 in next three months.

Dr Reddy's Lab top pick in pharma: IIFL Capital

Bino Pathiparampil of IIFL Capital told CNBC-TV18 that there has been a major rally in the sector over the last couple of years. Thus, many of the stocks went up 20 percent in the last couple of months itself.

Switch to Cipla from Ranbaxy Labs: Joshi

Sharmila Joshi, Head of Equity, Peerless Securities is of the view that one can switch to Cipla from Ranbaxy Laboratories.

Sell Ranbaxy, says Sudarshan Sukhani

Sudarshan Sukhani of s2analytics.com is of the view that one can sell Ranbaxy Laboratories.

6 trading bets that can fetch you handsome returns

Manas Jaiswal of manasjaiswal.com has recommended a buy rating on Adani Power and Dena Bank.

Above Rs 440, Ranbaxy uptrend likely to be over: Bothra

Kunal Bothra, Sr Technical Analyst of LKP is of the view that, if Ranbaxy Laboratories breaks at Rs 440 level in the next couple of days the short-term uptrend could more or less be over for the stock.

Short Ranbaxy Lab, Adani Enterprises: SP Tulsian

SP Tulsian of sptulsian.com is of the view that one can short Adani Enterprises with a target of Rs 239."Short Ranbaxy Laboratories with a target of Rs 440 and stop loss of Rs 448 ," he added.

See higher levels in Ranbaxy, says Sukhani

Sudarshan Sukhani of s2analytics.com feels that a new uptrend seems to be starting in Ranbaxy Laboratories.